Blog
1006 Articles
Let’s Talk About Rasonque: a Q&A for Our Community
Do you have questions about the newly approved drug Rasonque, generic name daraxonrasib? You can find all the answers on this page.
Updating My Story: Daraxonrasib Is Making a Difference
Catalina Fandino had a recurrence more than a year after her Whipple, but she qualified for daraxonrasib, which has changed her current path.
A New Era
For the physician-scientists at Johns Hopkins, research is leading to a new era in pancreatic cancer treatment.
One Year Later
For Douglas Cordova, recovering from a Whipple for his PNET was one step, one goal at a time. He is very glad to be back being Dad.
A New Approach to MEK Inhibition for First-Line Treatment
Dr. Eileen O’Reilly outlines a phase III trial of a targeted therapy for patients with metastatic pancreatic cancer.
Back to Normal
It took six months for Dr. Richard Dotson to get diagnosed, but after a Whipple procedure and chemo he feels back to normal.
Can AI Help Personalize Cancer Care?
PNET patient Burt Rosen experiments with AI to create a digital twin that provides insight into how he might respond to different treatments.
I’m Not Dead Yet
Long-term survivor Dr. Stephen Bigelsen knew how bad pancreatic cancer was and almost gave up, until his wife pushed him to learn more.
You’re Not Alone
Caregiver for her stage IV husband Stephen, Nancy Bigelsen credits the support of family and friends for helping them through his treatment.
The FDA Approves Rasonque™ (Daraxonrasib)
The FDA has approved Rasonque (daraxonrasib), the first drug approved to target KRAS in pancreatic cancer patients.
Could AI Help Detect the Pancreatic Cancers We Usually Miss?
Dr. Ajit Goenka is leading a team at the Mayo Clinic that is exploring how AI can be used to find random pancreatic cancer.
A Master Class in Self-Love
Wendy Hammers turned her pancreatic cancer diagnosis into life lessons for mental health, wellness, and focusing on joy.
At the Table: Looking Forward 10 Years
Members of the Patient Advisory Board discuss the changes they would like to see in 10 years in treatment, early detection, and managing care.
The Risk of a Dilated Pancreatic Duct
Dr. Mimi Canto and the team at Johns Hopkins have identified a dilated pancreatic duct as a risk factor for pancreatic cancer.
Surviving Will Someday Be the Expectation
Susan Ganis did not expect to be a survivor of pancreatic cancer, but she stayed positived and focused on the future.